Altoida is a health technology firm that uses digital biomarkers to drive better clinical outcomes for brain diseases. Led by a team of esteemed neuroscientists, physicians and computer scientists, the company offers a FDA and CE Mark-cleared medical device and brain health data platform to support early detection of Alzheimer’s disease up to ten years prior to onset – with up to 94% accuracy. The company is headquartered in Houston, TX, and has offices in San Diego, CA, and Lucerne, Switzerland.
Refreshed brand identity reflects Altoida’s emphasis on data and humanity, and will support the company’s growth as the world leader in Precision Neurology
2019/06/01New digital biomarkers company secures $6.3 MM in venture capital to detect Alzheimer’s disease 6-10 years prior to onset of Mild Cognitive Impairment (MCI) symptoms - with up to 94% accuracy
